Author

Silvio Danese

ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS
ASSOCIATION BETWEEN EFFICACY AND LONG-TERM OUTCOMES: FOUR YEAR RESULTS FROM THE UNIFI STUDY OF USTEKINUMAB IN ULCERATIVE COLITIS

Silvio Danese  et al.

52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION
52-WEEKS RISANKIZUMAB SUBCUTANEOUS MAINTENANCE DOSING IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO HAD DELAYED RESPONSE TO 12-WEEKS IV RISANKIZUMAB INDUCTION

Silvio Danese  et al.

REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY
REAL-WORLD UPTAKE OF STANDARD INDICES IN THE REPORTING OF ENDOSCOPY AND HISTOLOGY OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL SURVEY

Silvio Danese  et al.

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY

Silvio Danese  et al.

A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING
A CASE OF POST-GASTRECTOMY ANASTOMOTIC LEAKAGE REFRACTORY TO ENDOSCOPIC VACUUM THERAPY, SAVED BY COVERED ESOPHAGEAL STENTING

Silvio Danese  et al.

BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY
BENEFIT OF PROLONGED FILGOTINIB DOSING IN PATIENTS WITH ULCERATIVE COLITIS WHO DID NOT RESPOND TO INDUCTION THERAPY: DATA FROM THE SELECTION LONG-TERM EXTENSION STUDY

Silvio Danese  et al.

EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Silvio Danese  et al.

INVESTIGATING THE ROLE OF GUT EUKARYOTIC VIROME IN CONTRIBUTING TO COLORECTAL CANCER CARCINOGENESIS
INVESTIGATING THE ROLE OF GUT EUKARYOTIC VIROME IN CONTRIBUTING TO COLORECTAL CANCER CARCINOGENESIS

Silvio Danese  et al.

THE ROLE OF MFSD2A IN THE RESOLUTION OF COLORECTAL CANCER-PROMOTING INFLAMMATION: IMPLICATIONS FOR INNOVATIVE THERAPIES
THE ROLE OF MFSD2A IN THE RESOLUTION OF COLORECTAL CANCER-PROMOTING INFLAMMATION: IMPLICATIONS FOR INNOVATIVE THERAPIES

Silvio Danese  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Silvio Danese  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Silvio Danese  et al.

THE CAUDOVIRALES CLASS OF VIRUSES IS ASSOCIATED WITH DENDRITIC CELL IMPAIRMENT IN CD PATIENTS​​​​
THE CAUDOVIRALES CLASS OF VIRUSES IS ASSOCIATED WITH DENDRITIC CELL IMPAIRMENT IN CD PATIENTS​​​​

Silvio Danese  et al.

BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)
BASELINE SERUM BIOMARKERS PREDICT CLINICAL EFFICACY AND TISSUE MOLECULAR RESPONSE TO INDUCTION THERAPY WITH RITLECITINIB, AN ORAL JAK3/TEC INHIBITOR, IN ULCERATIVE COLITIS (UC) (PHASE 2B VIBRATO STUDY)

Silvio Danese  et al.

A CHALLENGING CASE OF DILATION-ASSISTED FULL THICKNESS RESECTION THROUGH A STOMIA OF A COLONIC RESIDUAL POST-MUCOSECTOMY SCAR
A CHALLENGING CASE OF DILATION-ASSISTED FULL THICKNESS RESECTION THROUGH A STOMIA OF A COLONIC RESIDUAL POST-MUCOSECTOMY SCAR

Silvio Danese  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Silvio Danese  et al.

HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY
HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: INTEGRATED RESULTS FROM THE PHASE 3 SERENE-UC STUDY

Silvio Danese  et al.

THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY
THERAPEUTIC DRUG MONITORING DOSING REGIMEN WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE SERENE-UC MAINTENANCE STUDY

Silvio Danese  et al.

ENDOSCOPIC VACUUM THERAPY (EVT) VERSUS SELF-EXPANDING METAL STENT (SEMS) IN THE TREATMENT OF NON-LARGE ANASTOMOTIC DEHISCENCES AFTER ONCOLOGIC IVOR-LEWIS ESOPHAGECTOMY: A MATCHED CASE-CONTROL STUDY
ENDOSCOPIC VACUUM THERAPY (EVT) VERSUS SELF-EXPANDING METAL STENT (SEMS) IN THE TREATMENT OF NON-LARGE ANASTOMOTIC DEHISCENCES AFTER ONCOLOGIC IVOR-LEWIS ESOPHAGECTOMY: A MATCHED CASE-CONTROL STUDY

Silvio Danese  et al.

TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA
TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Silvio Danese  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Silvio Danese  et al.

Item 101 - 120 / 152
1 2 3 4 5
6
7 8